Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 396

A Comparison of the Illness Experience Reported Via the Patient Reported Outcomes Measurement Information System Between Patients with Childhood-Onset Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, and Widespread Chronic Musculoskeletal Pain

9:00AM-11:00AM: Abstract Number: 405

Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 410

Characteristics of the Juvenile Systemic Sclerosis Cohort within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 408

Characterization of Pediatric Systemic Lupus Erythematosus with Acquired Angioedema

9:00AM-11:00AM: Abstract Number: 386

Chronic Arthritis in Systemic Lupus Erythematosus: Distinct Features in 336 Pediatric and 1,830 Adult Patients

9:00AM-11:00AM: Abstract Number: 421

Clinical Analysis and Outcome of Interstitial Lung Disease with Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 389

Clinical and Serological Differences Between Juvenile-Onset and Adult-Onset Systemic LUPUS Erythematosus Patients from a National Registry of Patients

9:00AM-11:00AM: Abstract Number: 398

Clinical and Serological Profile of Children with Positive SSA-Ro/SSB-La Antibodies

9:00AM-11:00AM: Abstract Number: 394

Clinical Features of Children with Silent Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 391

Current Provider Practices and Perceived Barriers for Mental Health Care of Adolescents with SLE

9:00AM-11:00AM: Abstract Number: 395

Depression Risk Among Adults with Childhood- and Adult-Onset Systemic Lupus Erythematosus: 11 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 420

Description of the Juvenile Localized Scleroderma Subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 419

Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 415

Development of a Juvenile Systemic Sclerosis Response Index (JSSRI)

9:00AM-11:00AM: Abstract Number: 400

Disease Activity and Health Care Utilization Among Young Adults with Childhood-Onset Lupus Transitioning to Adult Care: Data from the Pediatric Lupus Outcomes Study

9:00AM-11:00AM: Abstract Number: 409

Disease Activity, Disease Damage and Predictive Factors in Juvenile Onset Mixed Connective Tissue Disease – a Norwegian Nationwide Study

9:00AM-11:00AM: Abstract Number: 387

Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study

9:00AM-11:00AM: Abstract Number: 393

From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 392

From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

9:00AM-11:00AM: Abstract Number: 417

Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 425

Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus

9:00AM-11:00AM: Abstract Number: 423

Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database

9:00AM-11:00AM: Abstract Number: 407

Inter-Observer Variability of the Histological Classification of Lupus Glomerulonephritis in Children

9:00AM-11:00AM: Abstract Number: 413

Is There a Difference in the Presentation of Diffuse and Limited Subtype of Juvenile Systemic Sclerosis in Childhood? Results from the Juvenile Scleroderma Inception Cohort Www.Juvenile-Scleroderma.Com

9:00AM-11:00AM: Abstract Number: 406

Long Term Follow up of Inner City Pediatric Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 404

Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 397

Longitudinal Observation of Psychological Factors and Health-Related Quality of Life in Childhood-Onset Lupus

9:00AM-11:00AM: Abstract Number: 424

Magnetic Resonance and Echocardiographic Strain Rate Imaging for the Early Detection of Cardiac Involvement in Juvenile Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 399

Management of Lupus Anticoagulant Hypoprothrombinemia Syndrome in Juvenile Systemic Lupus Erythematosus – Single Center Experience

9:00AM-11:00AM: Abstract Number: 422

Mood Disorder Is Highly Prevalent in a Multi-Ethnic Urban Pediatric Lupus Cohort

9:00AM-11:00AM: Abstract Number: 388

Pain, Fatigue and the Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus

9:00AM-11:00AM: Abstract Number: 411

Patient Reported Outcomes in Juvenile Dermatomyositis: Assessing the Importance of Different Measures to Patients and Families

9:00AM-11:00AM: Abstract Number: 414

Performance of the Adult Systemic Sclerosis Classification in Juvenile Systemic Sclerosis Patients. Results from the Juvenile Systemic Sclerosis Inception Cohorte Www.Juvenile-Scleroderma.Com

9:00AM-11:00AM: Abstract Number: 402

Predicting Area Under the Curve of Mycophenolate Mofetil in Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 416

Prospective, Standardized, Longitudinal Assessment Reveals Higher Prevalence of Extracutaneous Manifestations in a Pediatric Localized Scleroderma Cohort

9:00AM-11:00AM: Abstract Number: 403

Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?

9:00AM-11:00AM: Abstract Number: 401

Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample

9:00AM-11:00AM: Abstract Number: 418

Relationship of Race, Ethnicity, and Outcomes in Pediatric Localized Scleroderma: Possible Differences in Disease Activity

9:00AM-11:00AM: Abstract Number: 426

The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 390

Treatment and Outcomes in Pediatric SLE Patients in South Africa

9:00AM-11:00AM: Abstract Number: 412

Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 50 Patients at First Assessment. Www.Juvenile-Scleroderma.Com

9:00AM-11:00AM: Abstract Number: 385

Urinary Cell-Free Microrna’s As Biomarkers of Lupus Nephritis in Children

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].